Clostridium difficile infections: An emerging problem in healthcare facilities

Reviews and Research in Medical Microbiology

Volumn 23, Issue 4, 2012, Pages 67-75

  Cristina, Maria Luisa ^a   Spagnolo, Anna Maria ^a   Sartini, Marina ^a   Panatto, Donatella ^a   Perdelli, Fernanda ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Clostridium difficile; emerging pathogens; hospital infections

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A1 ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN B1 ANTIBODY; CLOSTRIDIUM DIFFICILE VACCINE; METRONIDAZOLE; MONOCLONAL ANTIBODY; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SURVEILLANCE; HEALTH CARE FACILITY; HUMAN; HYGIENE; INCIDENCE; MEDICAL EDUCATION; MEDICAL STAFF; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REINFECTION; RELAPSE; SANITATION;

EID: 84867158405     PISSN: 0954139X     EISSN: 14735601     Source Type: Journal    
DOI: 10.1097/MRM.0b013e3283573643     Document Type: Article

References (81)

1. Kelly CP, LaMont JT. Clostridium difficile: more difficult than ever. N Engl J Med 2008; 359:1932-1940.
2. Kuipers EJ, Surawicz CM. Clostridium difficile infection. Lancet 2008; 371:1486-1488. (Pubitemid 351626174)
3. Heinlen L, Ballard JD. Clostridium difficile infection. Am J Med Sci 2010; 340:247-252.
4. Lyerly DM, Neville LM, Evans DT, Fill J, Allen S, Greene W, et al. Multicenter evaluation of the Clostridium difficile TOX A/ B test. J Clin Microbiol 1998; 36:184-190. (Pubitemid 28047456)
5. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals. Emerg Infect Dis 2006; 12:409-415.
6. Kuijper EJ, Coignard B, Tü ll P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12:2-18. (Pubitemid 44362038)
7. Swartz MN. Bacilli sporigeni aerobi: i clostridi [Aerobic sporogenous bacillus: Clostridium spp.]. In: Davis BD, Dulbecco R, Eisen HN, Ginsberg HS, editors. Microbiologia. 4th ed. Bologna: Zanichelli Editore; 1990. pp. 661.
8. Standards Unit, Evaluation and Standards Laboratory. Procedura sulle feci per Clostridium difficile [Faeces procedure for Clostridium difficile]. Metodo nazionale standard [National standard method]. 2007. tp://fad.italbioforma.it/ SOPS/ BSOP10.pdf. [Accessed 12 March 2012]
9. Sundriyal A, Roberts AK, Ling R, McGlashan J, Shone CC, Acharya KR. Expression, purification and cell cytotoxicity of actin-modifying binary toxin from Clostridium difficile. Protein Expr Purif 2010; 74:42-48.
10. Boetzkes A, Felkel KW, Zeiser J, Jochim N, Just I, Pich A.Secretome analysis of Clostridium difficile strains. Arch Microbiol 2012. doi: 10.1007/s00203-012-0802-5. [Epub ahead of print]
11. Carman RJ, Stevens AL, Lyerly MW, Hiltonsmith MF, Stiles BG, Wilkins TD. Clostridium difficile binary toxin (CDT) and diarrhea. Anaerobe 2011; 17:161-165.
12. De Lalla F, Orlando G, Pellizzer GP, Manfrin V. Infezioni dell'apparato digerente [Infections of the digestive system]. In: Moroni M, Esposito R, De Lalla F, editors. Malattie Infettive. 6th ed. Milan: Masson; 2003. pp. 449-521.
13. Toyokawa M, Ueda A, Tsukamoto H, Nishi I, Horikawa M, Sunada A, et al. Pseudomembranous colitis caused by toxin Anegative/ toxin B-positive variant strain of Clostridium difficile. J Infect Chemother 2003; 9:351-354. (Pubitemid 38031334)
14. Eckert C, Vromman FO, Halkovich A, Barbut F. Multilocus variable-number tandem repeat analysis: a helpful tool for subtyping French Clostridium difficile PCR ribotype 027 isolates. J Med Microbiol 2011; 60:1088-1094.
15. Valiente E, Dawson LF, Cairns MD, Stabler RA, Wren BW. Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage. J Med Microbiol 2012; 61:49-56.
16. Clements AC, Magalhaes RJ, Tatem AJ, Paterson DL, Riley TV. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010; 10:395-404.
17. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-1084. (Pubitemid 41338761)
18. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-2441. (Pubitemid 41770164)
19. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006; 73:187-197.
20. Stabler RA, Dawson LF, Valiente E, Cairns MD, Martin MJ, Donahue EH, et al. Macro and micro diversity of Clostridium difficile isolates from diverse sources and geographical locations. PLoS One 2012; 7:e31559.
21. Nyc O, Pituch H, Matejková J, Obuch-Woszczatynski P, Kuijper EJ. Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland. Lancet 2011; 377:1407.
22. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7:526-536.
23. Wilcox MH, Dave J. Treatment options in Clostridium difficile infection. Rev Med Microbiol 2001; 12:21-28. (Pubitemid 32095752)
24. Suetens C. Clostridium difficile: summary of actions in the European Union. Euro Surveill 2008; 13:pii: 18944.
25. Vonberg RP, Reichardt C, Behnke M, Schwab F, Zindler S, Gastmeier P. Costs of nosocomial Clostridium difficileassociated diarrhea. J Hosp Infect 2008; 70:15-20.
26. Centers for Disease Control and Prevention (CDC). Vital Signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012;61:157-162.
27. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40:1-15. (Pubitemid 28438966)
28. Gaynes R, Rimland D, Killum E, Lowery HK, Johnson TM 2nd, Killgore G, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38:640-645. (Pubitemid 38333858)
29. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-1260. (Pubitemid 41532667)
30. Impallomeni M, Galletly NP, Wort SJ, Starr JM, Rogers TR. Increased risk of Clostridium difficile diarrhea in elderly patients receiving cefotaxime. Br Med J 1995; 311:1345-1346.
31. Vesta KS, Wells PG, Gentry CA, Stipek WJ. Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluation. Am J Infect Control 2005; 33:469-472. (Pubitemid 41433330)
32. Jacobs A, Barnard K, Fishel R, Gradon JD. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2001; 80:88-101. (Pubitemid 32285206)
33. Duthilly A, Blanckaert K, Thielemans B, Simon M, Cattoen C. Clostridium difficile bacteremia. Presse Med 2001; 30:1825-1826.
34. García-Lechuz JM, Hernangómez S, Juan RS, Peláez T, Alcalá L, Bouza E. Extra-intestinal infections caused by Clostridium difficile. Clin Microbiol Infect 2001; 7:453-457. (Pubitemid 34960340)
35. Karlström O, Fryklund B, Tullus K, Burman LG. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group. Clin Infect Dis 1998; 26:141-145. (Pubitemid 28068168)
36. Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile- associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006; 175:745-748. (Pubitemid 44520987)
37. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008; 70:298-304.
38. Barbut F, Delmée M, Brazier JS, Petit JC, Poxton IR, Rupnik M, et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 2003; 9:989-996. (Pubitemid 37361827)
39. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-2449. (Pubitemid 41770165)
40. Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, et al. Healthcare-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010; 50:194-201.
41. Office for National Statistics. Deaths involving Clostridium difficile: England and Wales, 2001-2005. Health Stat Q 2007; 33:71-75.
42. Office for National Statistics. Deaths involving Clostridium difficile: England and Wales, 1999 and 2001-06. Health Stat Q 2008; 37:52-56.
43. McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003; 9:730-733. (Pubitemid 36676373)
44. Burns K, Morris-Downes M, Fawley WN, Smyth E, Wilcox MH, Fitzpatrick F. Infection due to C. difficile ribotype 078: first report of cases in the Republic of Ireland. J Hosp Infect 2010; 75:287-291.
45. Baldan R, Cavallerio P, Tuscano A, Parlato C, Fossati L, Moro M, et al. First report of hypervirulent strains polymerase chain reaction ribotypes 027 and 078 causing severe Clostridium difficile infection in Italy. Clin Infect Dis 2010; 50:126-127.
46. Janezic S, Ocepek M, Zidaric V, Rupnik M. Clostridium difficile genotypes other than ribotype 078 that are prevalent among human, animal and environmental isolates. BMC Microbiol 2012; 12:48.
47. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk: four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1201-1205.
48. Centers for Disease Control and Prevention. Surveillance for community-associated Clostridium difficile: Connecticut, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:340-343.
49. McCollum DL, Rodriguez JM. Detection, treatment, and prevention of Clostridium difficile infection. Clin Gastroenterol Hepatol 2012; 10:581-592.
50. Caprioli A, Luzzi I, Lana S. Sorveglianza e prevenzione delle infezioni Gastroenteriche [Surveillance and prevention of gastrointestinal infections]. Istituto Superiore di Sanita. ISTISAN Congressi 05/C12. http://www.iss.it/ binary/publ/publi/05-C12.1133170606.pdf. [Accessed 2 April 2012]
51. Health Protection Agency. Clostridium difficile infection: how to deal with the problem. 2009. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/ 1232006607827. [Accessed 12 March 2012]
52. Deshpande A, Pasupuleti V, Pant C, Hall G, Jain A. Potential value of repeat stool testing for Clostridium difficile stool toxin using enzyme immunoassay? Curr Med Res Opin 2010; 26:2635-2641.
53. Jaber MR, Olafsson S, Fung WL, Reeves ME. Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastroenterol 2008; 103:3195-3203.
54. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-1775. (Pubitemid 34761404)
55. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-307. (Pubitemid 47101025)
56. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995; 44:1-13.
57. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
58. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346:334-349.
59. Miller MA. Clinical management of Clostridium difficileassociated disease. Clin Infect Dis 2007; 45:S122-S128. (Pubitemid 47328626)
60. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficileassociated disease. J Clin Gastroenterol 2004; 38:414-418.
61. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-1590. (Pubitemid 40720807)
62. Pepin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007; 102:2781-2788. (Pubitemid 350179349)
63. Louie T, Gerson M, Grimard D, Johnson S, Poirier A, Weiss K, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD) [abstract K-425]. In: Proceedings of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, Illinois, USA. Washington, District of Columbia: ASM Press; 2007.
64. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205.
65. Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012; 28:1-9.
66. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhea. Gut 2001; 49:152-153.
67. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20:43-50.
68. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80:867-868. (Pubitemid 16233533)
69. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 2005; 54:101-111. (Pubitemid 40867993)
70. Wilcox MH, Fawley WN, Settle CD, Davidson A. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J Hosp Infect 1998; 38:93-100. (Pubitemid 28143351)
71. Maroo S, Lamont JT. Recurrent Clostridium difficile. Gastroenterology 2006; 130:1311-1316.
72. Best EL, Fawley WN, Parnell P, Wilcox MH. The potential for airborne dispersal of Clostridium difficile from symptomatic patients. Clin Infect Dis 2010; 50:1450-1457.
73. Blot E, Escande MC, Besson D, Barbut F, Granpeix C, Asselain B, et al. Outbreak of Clostridium difficilerelated diarrhea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect 2003; 53:187-192. (Pubitemid 38002053)
74. Pulvirenti JJ, Gerding DN, Nathan C, Hafiz I, Mehra T, Marsh D, et al. Difference in the incidence of Clostridium difficile among patients infected with human immunodeficiency virus admitted to a public hospital and a private hospital. Infect Control Hosp Epidemiol 2002; 23:641-647. (Pubitemid 35315985)
75. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial Clostridium difficile colonization and disease. Lancet 1990; 336:97-100. (Pubitemid 20222816)
76. Kuijper EJ, de Weerdt J, Kato H, Kato N, van Dam AP, van der Vorm ER, et al. Nosocomial outbreak of Clostridium difficile-associated diarrhea due to a clindamycin-resistant enterotoxin A-negative strain. Eur J Clin Microbiol Infect Dis 2001; 20:528-534. (Pubitemid 32905528)
77. Verity P, Wilcox MH, Fawley W, Parnell P. Prospective evaluation of environmental contamination by Clostridium difficile in isolation side rooms. J Hosp Infect 2001; 49:204-209. (Pubitemid 33072154)
78. Wilcox MH, Fawley WN, Wigglesworth N, Parnell P, Verity P, Freeman J. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 2003; 54:109-114. (Pubitemid 38002007)
79. Gordin FM, Schultz ME, Huber RA, Gill JA. Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol based hand rub. Infect Control Hosp Epidemiol 2005; 26:650-653. (Pubitemid 41073407)
80. McNulty C, Logan M, Donald IP, Ennis D, Taylor D, Baldwin RN, et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997; 40:707-711. (Pubitemid 27504003)
81. Vonberg RP, Kuijper EJ, Wilcox MH, Barbut F, Tü ll P, Gastmeier P, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14:2-20. (Pubitemid 351560386)